Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last €49.67 EUR
Change Today +0.126 / 0.25%
Volume 0.0
As of 1:34 PM 08/3/15 All times are local (Market data is delayed by at least 15 minutes).

nuvasive inc (NK8) Snapshot

Previous Close
Day High
Day Low
52 Week High
07/30/15 - €50.80
52 Week Low
10/15/14 - €26.07
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for NUVASIVE INC (NK8)

nuvasive inc (NK8) Related Businessweek News

No Related Businessweek News Found

nuvasive inc (NK8) Details

NuVasive, Inc., a medical device company, develops and markets minimally-disruptive surgical products and procedurally-integrated solutions for the spine. Its products focus on applications for spine fusion surgery. The company’s principal product is Maximum Access Surgery (MAS), a minimally-disruptive surgical platform that includes its proprietary software-driven nerve detection and avoidance systems, NVM5 and NVJJB, and intra-operative monitoring (IOM) services and support; MaXcess, an integrated split-blade retractor system; and various specialized implants and biologics. Its spine surgery product line offerings comprise products for the thoracolumbar and the cervical spine, which are primarily used to enable surgeons access to the spine and to perform restorative and fusion procedures in a minimally disruptive fashion. The company’s biologic product line offerings used to aid the spinal fusion process or bone healing process consist of Osteocel Plus and Osteocel Pro allograft (donated human tissue), which are cellular matrix products containing viable mesenchymal stem cells; FormaGraft, a collagen synthetic product; and AttraX, a synthetic bone graft material. It also provides IOM services for insight into the nervous system during non-spine. The company sells its products through independent sales agencies, directly-employed sales shareowners to surgeons and hospitals in the United States and internationally. NuVasive, Inc. was founded in 1997 and is headquartered in San Diego, California.

1,500 Employees
Last Reported Date: 02/25/15
Founded in 1997

nuvasive inc (NK8) Top Compensated Officers

President and Chief Operating Officer
Total Annual Compensation: $545.7K
Chief Financial Officer, Chief Accounting Off...
Total Annual Compensation: $380.5K
President of U.S. Commercial
Total Annual Compensation: $375.0K
Executive Vice President of International and...
Total Annual Compensation: $454.1K
Total Annual Compensation: $900.0K
Compensation as of Fiscal Year 2014.

nuvasive inc (NK8) Key Developments

NuVasive, Inc. Appoints Jason Hannon as Executive Vice President, International

NuVasive Inc. announced the appointment of Jason Hannon as Executive Vice President, International. In his new role, he will be responsible for the company's business and commercial operations outside of the United States. Hannon will be relocating to NuVasive's International headquarters in Amsterdam, the Netherlands where he will drive the Company's international expansion strategy. Hannon will continue to serve as NuVasive's General Counsel until a successor is identified, for which an active search is underway.

NuVasive, Inc. Announces Executive Changes

Effective as of July 9, 2015, the Board of Directors of, Inc. accepted the resignation of Dr. Peter Leddy, Ph.D. as a director. Dr. Leddy resigned from the Board in connection with his appointment as the company's Executive Vice President, Human Resources and Corporate Integrity. In this new role, Dr. Leddy will serve as an executive officer of the company with leadership responsibilities for the company's human resources, compliance, regulatory and facilities functions. On July 13, 2015, the company appointment Dr. Leddy as Executive Vice President, Human Resources and Corporate Integrity, as well as other additions and changes in roles and responsibilities of the company's executive leadership team. NuVasive’s executive leadership team, reporting directly to Mr. Lucier, includes: Jason Hannon, Executive Vice President, International and General Counsel: Mr.Hannon assumes the role of Executive Vice President, International from Russell Powers, who continues to serve as an Executive Vice President and a member of the executive leadership team at NuVasive and will focus on NuVasive’s expansion into greater China. Mr. Hannon has extensive experience at NuVasive in the areas of corporate development, mergers and acquisitions, and regulatory and legal. In his new role, Mr. Hannon will be responsible for NuVasive’s business and commercial operations outside of the United States, including leading the company’s international expansion opportunities. Carol Cox, Executive Vice President, Strategy, Corporate Development and External Affairs: Ms. Cox assumes the role of Executive Vice President, Strategy, Corporate Development and External Affairs. Ms. Cox has more than 20 years of senior level experience in cross-functional corporate roles in the healthcare sector. She joined the company in 2014, most recently serving as Executive Vice President of Corporate Affairs and Human Resources. In her new role, Ms. Cox will be responsible for leading NuVasive’s corporate development and mergers and acquisitions strategy, leveraging communications, investor relations and government affairs channels in support of the company’s strategic priorities, and creating a corporate marketing and brand team. Pete Leddy, Ph.D, Executive Vice President, Human Resources and Corporate Integrity: Dr. Leddy assumes leadership of the company’s human resources, compliance, regulatory and facilities functions after serving as a member of NuVasive’s Board of Directors since 2011. In addition, NuVasive has begun a search for a Chief Information Officer, a newly created role, and a new General Counsel to replace Mr. Hannon, both of whom would also be part of the executive leadership team and report to Mr. Lucier.

Nuvasive, Inc. Elects Daniel J. Wolterman as Board of Director

NuVasive, Inc. announced that Daniel J. Wolterman has been elected to the company’s board of directors. It is expected that Mr. Wolterman will also serve on the board’s compensation committee. Mr. Wolterman has been president and CEO of Memorial Hermann Health System since 2002. He has more than 30 years of experience in the healthcare industry and a long history of community involvement. He serves on the Joint Commission’s Center for Transforming Healthcare Leadership Advisory Council, and he continues to serve on the Greater Houston Partnership, and Voluntary Hospitals of America boards of directors. He previously served on the board of directors of Volcano Corporation until the completion of its acquisition by Royal Philips in February of this year. Mr. Wolterman is also an Adjunct Professor at The University of Texas School of Public Health.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
NK8:GR €49.67 EUR +0.126

NK8 Competitors

Market data is delayed at least 15 minutes.

Company Last Change
CONMED Corp $56.85 USD +0.13
Globus Medical Inc $27.56 USD -0.50
Integra LifeSciences Holdings Corp $64.08 USD -0.05
Masimo Corp $41.05 USD -0.63
Thoratec Corp $63.44 USD +0.15
View Industry Companies

Industry Analysis


Industry Average

Valuation NK8 Industry Range
Price/Earnings 57.2x
Price/Sales 3.4x
Price/Book 4.0x
Price/Cash Flow 45.2x
TEV/Sales 2.6x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact NUVASIVE INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at